1. Home
  2. BNL vs MLYS Comparison

BNL vs MLYS Comparison

Compare BNL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNL
  • MLYS
  • Stock Information
  • Founded
  • BNL 2007
  • MLYS 2019
  • Country
  • BNL United States
  • MLYS United States
  • Employees
  • BNL N/A
  • MLYS N/A
  • Industry
  • BNL Real Estate Investment Trusts
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BNL Real Estate
  • MLYS Health Care
  • Exchange
  • BNL Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • BNL 3.5B
  • MLYS 3.1B
  • IPO Year
  • BNL 2020
  • MLYS 2023
  • Fundamental
  • Price
  • BNL $18.45
  • MLYS $38.11
  • Analyst Decision
  • BNL Buy
  • MLYS Strong Buy
  • Analyst Count
  • BNL 7
  • MLYS 6
  • Target Price
  • BNL $19.71
  • MLYS $42.60
  • AVG Volume (30 Days)
  • BNL 1.6M
  • MLYS 1.5M
  • Earning Date
  • BNL 10-29-2025
  • MLYS 11-10-2025
  • Dividend Yield
  • BNL 6.26%
  • MLYS N/A
  • EPS Growth
  • BNL N/A
  • MLYS N/A
  • EPS
  • BNL 0.52
  • MLYS N/A
  • Revenue
  • BNL $442,203,000.00
  • MLYS N/A
  • Revenue This Year
  • BNL $4.91
  • MLYS N/A
  • Revenue Next Year
  • BNL $5.98
  • MLYS N/A
  • P/E Ratio
  • BNL $35.72
  • MLYS N/A
  • Revenue Growth
  • BNL 3.85
  • MLYS N/A
  • 52 Week Low
  • BNL $13.96
  • MLYS $8.24
  • 52 Week High
  • BNL $18.86
  • MLYS $41.09
  • Technical
  • Relative Strength Index (RSI)
  • BNL 56.74
  • MLYS 62.93
  • Support Level
  • BNL $17.53
  • MLYS $37.48
  • Resistance Level
  • BNL $18.75
  • MLYS $40.91
  • Average True Range (ATR)
  • BNL 0.29
  • MLYS 2.15
  • MACD
  • BNL -0.01
  • MLYS -0.88
  • Stochastic Oscillator
  • BNL 77.46
  • MLYS 30.13

About BNL Broadstone Net Lease Inc.

Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: